triazolam has been researched along with Dementia in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cotroneo, A | 1 |
| Gareri, P | 1 |
| Nicoletti, N | 1 |
| Lacava, R | 1 |
| Grassone, D | 1 |
| Maina, E | 1 |
| De Sarro, G | 1 |
| Cabodi, S | 1 |
1 other study available for triazolam and Dementia
| Article | Year |
|---|---|
Effectiveness and safety of hypnotic drugs in the treatment of insomnia in over 70-year old people.
Topics: Aged; Cognition Disorders; Dementia; Depression; Drug Administration Schedule; Female; Health Status | 2007 |